Skip to main content
OpenTrials
Completed

NCT Number: NCT03617640

Neuro-Immune Interactions in the Gut

Hirschsprung's disease (HD) is diagnosed shortly after birth and is characterized by the presence of megacolon. HD is caused when ganglion cells of the enteric nervous system (ENS) in the wall of the large intestine do not develop before birth. This results in a lack of gastrointestinal motility and leads to stool obstruction. It is known that ablation of enteric nerves is associated with intestinal infection and inflammation. Indeed the most severe complication in HD is Hirschsprung's associated enterocolitis (HAEC), characterized by explosive diarrhea, abdominal distension, fever and impending septic shock. Bacteria overgrowth and changes in colonic mucosal immune cell populations during HAEC suggest a possible defect in mucosal immune homeostasis. Under steady state conditions, the mucosal immune system must be tightly controlled to avoid harmful reactions against commensal flora and food antigens, while allowing protective immune responses against invading pathogens. This balance between tolerance and defense is influenced by the mucosal microenvironment, which in turn determines the phenotype and stability of mucosal immune cell populations. The goal of this project is to understand if the enteric nervous system plays a role in regulating mucosal immunity and how this might contribute to the development of HAEC.

Completed

Looking for future studies?

Notify Me

Key information

Age range

0 month–18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Kinderchirurgie Universität Heidelberg, Heidelberg, Germany

Loading trial locations.

About this study

Hirschsprung's disease (HD) is diagnosed shortly after birth and is characterized by the absence of enteric nerves in parts of colon [Amiel et al.]. Following surgical correction many patients develop HD-associated enterocolitis (HAEC), a condition distinguished by intestinal inflammation resulting in abdominal distension, severe diarrhea, fever and sepsis [Demehri et al.]. The underlying factors leading to HAEC remain poorly understood and likely involve a defect in epithelial barrier, including decreased mucin production and insufficient immunoglobulin translocation. The establishment of the epithelial barrier is dependent on epithelial recognition of microbial products by innate immune receptors, like toll-like receptors (TLRs) [Peterson et al.]. TLR-dependent epithelial recognition of microflora also coordinates the immune response away from harmless commensal bacteria and towards pathogenic invaders. Both innate and adaptive effector cell functions are influenced by epithelial-derived signals. Under homeostatic conditions commensal bacteria induce anti-inflammatory cytokines in epithelial cells which trigger a tolerogenic phenotype in mucosal antigen presenting cells (APC) resulting in generation of commensal-specific regulatory T cells (Tregs) [Curotto de Lafaille et al.]. During infection, recognition of pathogenic organisms by epithelial cells leads to secretion of inflammatory cytokines thereby inducing an inflammatory APC phenotype which promotes T effector cell (Th1, Th17) generation. The enteric nervous system is directly located underneath the epithelium and controls epithelial cell function. Ablation of enteric glia cells, one of the two cell types of the ENS, in mice is associated with inflammation and enterocolitis [Cornet et al.]. In a study from 2011 Flamant and co-workers demonstrate that enteric glia cells protect from a shigella flexneri invasion by preventing lesions in the epithelial barrier mediated by the glia cell derived neurothrophic factor S-nitrosoglutathione (GSNO) [Flamant et al.]. We hypothesize that the lack of an enteric nervous system in HD patients modulates the microbial recognition of epithelial cells and thereby the phenotype of underlying mucosal APCs and effector T cells; this might be associated with the manifestation of HAEC.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Informed consent

Exclusion criteria

No signed informed consent No blood from patients with weak general state of health

Treatment and study plan

Primary outcomes

  1. Phenotypic analysis of immune and nervous cell populations

    Time frame: 5 years

    Determining cell frequencies and subtypes using fluorescence-activated cell sorting (FACS) and FlowJo software

  2. Expression profil

    Time frame: 5 years

    RNA expression profile of whole colon tissue and single cell populations

  3. Histological analysis

    Time frame: 5 years

    Microscopic analysis of colonic tissue using immunofluorescence and immunohistochemistry

Secondary outcomes

  1. Microbial metagenomics sequencing

    Time frame: 5 years

    16S/18S/ITS Amplicon

  2. Identifying genetic defect

    Time frame: 5 years

    Targeted Sanger sequencing of known Hirschsprung's disease associated genes

Sponsors and collaborators

Lead sponsor

University Children's Hospital Basel

Other

Collaborators

  • Bâtiment Hospitalier CHUV
  • Hôpitaux Universitaires Genève
  • Insel Gruppe AG, University Hospital Bern
  • Kinderspital St. Gallen
  • Luzerner Kantonsspital
  • Ospedale Regionale di Bellinzona e Valli
  • University Children's Hospital, Zurich
  • University Hospital Heidelberg

Registry information

Official study title

The Enteric Nervous System as Modulator of Mucosal Immune Cells

Acronym: NIG

Important dates

Study start
2015
Primary completion
2022
Study completion
2022
First posted
Aug 6, 2018
Registry last updated
Nov 4, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.